The Trader Harbor
  • Business
  • Politics
  • World News
  • Stocks
  • Business
  • Politics
  • World News
  • Stocks

The Trader Harbor

Business

Pfizer CEO says tariff uncertainty is deterring further U.S. investment in manufacturing, R&D

by admin April 30, 2025
April 30, 2025
Pfizer CEO says tariff uncertainty is deterring further U.S. investment in manufacturing, R&D

Pfizer CEO Albert Bourla on Tuesday said uncertainty around President Donald Trump’s planned pharmaceutical tariffs is deterring the company from further investing in U.S. manufacturing and research and development. 

Bourla’s remarks on the company’s first-quarter earnings call came in response to a question about what Pfizer wants to see from tariff negotiations that would push the company to increase investments in the U.S. It comes as drugmakers brace for Trump’s levies on pharmaceuticals imported into the country — his administration’s bid to boost domestic manufacturing.

“If I know that there will not be tariffs … then there are tremendous investments that can happen in this country, both in R&D and manufacturing,” Bourla said on the call, adding that the company is also hoping for “certainty.”

“In periods of uncertainty, everybody is controlling their cost as we are doing, and then is very frugal with their investment, as we are doing, so that we are prepared for remit. So that’s what I want to see,” Bourla said.

Bourla noted the tax environment, which had previously pushed manufacturing abroad, has “significantly changed now” with the establishment of a global minimum tax of around 15%. He said that shift hasn’t necessarily made the U.S. more attractive, saying “it’s not as good” to invest here without additional incentives or clarity around tariffs.

“Now [Trump] I’m sure — and I know because I talked to him — that he would like to see even a reduction in the current tax regime particularly for locally produced goods,” Bourla said, adding a further decrease would be would be a strong incentive for manufacturing in the U.S.

Unlike other companies grappling with evolving trade policy, Pfizer did not revise its full-year outlook on Tuesday. However, the company noted in its earnings release that the guidance “does not currently include any potential impact related to future tariffs and trade policy changes, which we are unable to predict at this time.”

But on the earnings call on Tuesday, Pfizer executives said the guidance does reflect $150 million in costs from Trump’s existing tariffs.

“Included in our guidance that we didn’t really speak about is there are some tariffs in place today,” Pfizer CFO Dave Denton said on the call.

“We are contemplating that within our guidance range and we continue to again trend to the top end of our guidance range even with those costs to be incurred this year,” he said.

This post appeared first on NBC NEWS

0
FacebookTwitterGoogle +Pinterest
previous post
JetBlue to partner with another U.S. airline in the coming weeks
next post
President Trump gave me back my life after 471 days of Hamas captivity — please save the remaining hostages

Related Posts

McDonald’s Snack Wrap is officially returning. Here’s when.

June 4, 2025

Some experts have raised the odds of a...

August 15, 2024

Nvidia’s CEO did a Q&A with analysts. What...

March 26, 2025

As inflation cools, Social Security could pay out...

July 12, 2024

U.S. airlines cut growth plans in a bid...

July 31, 2024

Dave & Buster’s plan to allow betting on...

May 8, 2024

Mortgage rates plunge to the lowest level in...

August 6, 2024

Microsoft confirms performance-based job cuts across departments

January 11, 2025

Mars to acquire snack maker Kellanova in $36...

August 15, 2024

Aviation incidents seem to be proliferating, but experts...

March 10, 2024

    Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Latest

    • Orange juice importer says Brazil tariffs will squeeze American consumers

      July 23, 2025
    • The Real Drivers of This Market: AI, Semis & Robotics

      July 23, 2025
    • Tech Taps the Brakes, Homebuilders Hit the Gas: See the Rotation on StockCharts Today

      July 23, 2025
    • GOP lawmakers advocate for US condemnation of persecution against Christians in Muslim-majority nations

      July 23, 2025
    • ‘Not going away’: Inside the Epstein drama that’s thrown House GOP into chaos

      July 23, 2025
    • Obama denies Trump’s ‘bizarre allegations’ that he was Russiagate ‘ringleader’ in rare statement

      July 23, 2025

    Categories

    • Business (1,300)
    • Politics (4,060)
    • Stocks (1,538)
    • Uncategorized (45)
    • World News (1,293)
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: TheTraderHarbor, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 thetraderharbor.com | All Rights Reserved